PainReform Ltd. Stock Price

NasdaqCM:PRFX Community·US$2.3m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

PRFX Share Price Performance

US$1.05

-0.93 (-46.98%)

US$1.05

-0.93 (-46.98%)

US$1.05

Wed, 5 Nov 25

Share PriceUS$1.05

PRFX Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

6 Risks

0 Rewards

View Full Analysis

PainReform Ltd. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -2.03
: 0%
: 0%
: 0%

View Full Analysis

About PRFX

Founded: 2007
Employees: 4
CEO: Ehud Geller
WebsiteView website: www.painreform.com

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.